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Invited Review
Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2
water channel in nephrogenic diabetes insipidus
Joris H. Robben, Nine V. A. M. Knoers, and Peter M. T. Deen
Department of Physiology, Nijmegen Centre for Molecular Life Sciences and Human
Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Robben, Joris H., Nine V. A. M. Knoers, and Peter M. T. Deen. Cell
biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel
in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 291: F257–F270,
2006; doi:10.1152/ajprenal.00491.2005.—In the renal collecting duct, water reab-
sorption is regulated by the antidiuretic hormone vasopressin (AVP). Binding of
this hormone to the vasopressin V2 receptor (V2R) leads to insertion of aqua-
porin-2 (AQP2) water channels in the apical membrane, thereby allowing water
reabsorption from the pro-urine to the interstitium. The disorder nephrogenic
diabetes insipidus (NDI) is characterized by the kidney’s inability to concentrate
pro-urine in response to AVP, which is mostly acquired due to electrolyte distur-
bances or lithium therapy. Alternatively, NDI is inherited in an X-linked or
autosomal fashion due to mutations in the genes encoding V2R or AQP2, respec-
tively. This review describes the current knowledge of the cell biological causes of
NDI and how these defects may explain the patients’ phenotypes. Also, the
increased understanding of these cellular defects in NDI has opened exciting
initiatives in the development of novel therapies for NDI, which are extensively
discussed in this review.
osmoregulation; protein trafficking; genetic disorder; collecting duct; lithium;
pharmacological chaperones
MAINTAINING BODY WATER HOMEOSTASIS is of vital importance for
proper functioning of most physiological processes in the
human body. Under normal conditions, the glomerular filtra-
tion rate (GFR) of the two kidneys amounts 180 l/day. Of this
huge volume, also called the pro-urine, 90% is reabsorbed in
the proximal tubule and descending limb of Henle’s loop,
which is a constitutive process. According to need, the remain-
ing fluid can be reabsorbed in the collecting duct. This process
is tightly regulated by an elegant system, which allows the
body to adapt to periods of water load or water restriction. The
key hormone in this process is the antidiuretic hormone argi-
nine-vasopressin (AVP), which is secreted by the posterior
pituitary in response to states of hypovolemia or hypernatremia
(94). In healthy individuals, secreted AVP will be transported
by the blood to the kidney, where it can bind to vasopressin V2
receptors (V2R), which are mainly present on the basolateral
(interstitial) side of the principal collecting duct cells (112).
The activated V2R will induce an increase of intracellular
cAMP levels via the stimulatory Gs protein and adenylate
cyclase, which will eventually lead to activation of protein
kinase A and to phosphorylation of aquaporin-2 (AQP2) water
channels (45, 68). Phosphorylation of at least three of four
monomers of an AQP2 tetramer is then sufficient to redistrib-
ute AQP2 homotetramers from storage vesicles to the apical
membrane, rendering this membrane permeable to water (63,
157). Following an osmotic gradient of sodium and urea, water
will then pass the apical membrane via AQP2 and will leave
the cells on the basolateral side via AQP3 and AQP4 (57, 69),
thereby compensating for the hypovolemic or hypernatremic
state of the body. This process is summarized in Fig. 1. When
sufficient water is reabsorbed to restore homeostasis, serum
vasopressin levels will decrease (94), and AQP2 will be inter-
nalized from the apical membrane, resulting in decreased water
reabsorption. Katsura et al. (67) showed that this AVP-regu-
lated recycling of AQP2 can occur at least six times with the
same repertoire of AQP2 molecules. In addition to its direct
regulation of water transport, AVP also increases sodium
transport in the collecting duct via the epithelial sodium chan-
nel (ENaC) (8, 38) and urea transport via the UT-A1 trans-
porter (141).
Malfunctioning of water reabsorption can lead to a variety of
disorders, which can be of central or renal origin. Centrally, in
the syndrome of inappropriate secretion of antidiuretic hor-
mone, AVP levels are abnormally increased, leading to exces-
sive renal water reabsorption, which might result in life-
threatening hyponatremia (118). The most common causes of
the syndrome of inappropriate secretion of antidiuretic hor-
mone are neoplasia, like nonmalignant lung carcinoma, neu-
rological disorders, congestive heart failure, liver cirrhosis,
preeclampsia, and drugs like thiazide diuretics or selective
serotonin reuptake inhibitor antidepressants. These effects
have recently been reviewed in more detail and will not be
discussed here (11, 110).
At the other extreme is diabetes insipidus (DI), in which
patients are unable to concentrate their urine, resulting in
polyuria and, consequently, polydipsia. With central DI, hu-
mans lack the ability to produce functional AVP and therefore
to actively concentrate their urine. Sometimes, this is due to
Address for reprint requests and other correspondence: P. M. T. Deen,
286-Dept. Physiology, RUNMC, Nijmegen/NCMLS, PO Box 9101, 6500 HB
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AVP gene mutations (3, 6, 44, 48, 128). Administration of the
synthetic AVP homolog 1-desamino-8-D-arginine vasopressin
(DDAVP), however, is usually able to drastically decrease
urine output in these patients. A well-studied disturbance of
water homeostasis, and the main topic of this review, is
nephrogenic diabetes insipidus (NDI). In this disorder, patients
are unable to concentrate their urine, despite increased serum
AVP levels. This review focuses on the molecular causes
underlying NDI and how this information may aid in identi-
fying novel therapies for this disorder.
ACQUIRED NDI
Most commonly, NDI is acquired due to several conditions,
which can be divided into three different groups.
Electrolyte Disturbances
Two clinically important electrolyte abnormalities, hypoka-
lemia and hypercalcemia, lead to polyuria and urinary concen-
tration effects. Hypokalemia is found in up to 21% of hospi-
talized patients, develops in 50% of patients with secondary
hyperaldosteronism or using furosemide/thiazide diuretics, and
may lead to the development of polyuria, NDI, and reduced
AQP2 expression (89, 171). Indeed, in potassium-deprived
rats, a 70% reduction in expression and a redistribution from
the plasma membrane to intracellular vesicles were observed
for AQP2 compared with control rats (89). This effect has been
attributed to a reduced pituitary AVP release, blunted renal
response to AVP, intrarenal PGE2 production, and impaired
AVP-sensitive adenylate cyclase, but might also be due to a
reduced interstitial tonicity, as hypokalemia-induced NDI co-
incides with a severe downregulation of major renal sodium
and urea transporters (39, 60), and an elevated tonicity in-
creases AQP2 expression in vitro (50, 66, 151).
Hypercalcemia, which is mostly due to primary hyperpara-
thyroidism and malignancies such as lytic bone disease or
humoral hypercalcemia, causes NDI, leading to severe dehy-
dration (123). Studies using excess vitamin D or parathyroid
hormone rat models reveal that hypercalcemia-induced NDI is
accompanied by a reduced GFR and interstitial tonicity and an
increased urinary and fractional sodium excretion (166). The
reduced expression of type 2 Na-Pi cotransporter, type-3 Na/
H-exchanger, Na-K-ATPase, and Na-K-2Cl cotransporter in
hypercalcemia-induced NDI likely contributes to the increased
urinary sodium excretion and decreased urine concentration
(166). Moreover, hypercalcemia-induced NDI coincides with
diminished total and apical membrane expression of AQP2, at
normal AQP2 mRNA levels, whereas AQP3 expression is also
reduced (37, 165). The effects on AQP2 are ascribed to
activation of the apical calcium-sensing receptor (CaSR) by
hypercalciuria, which is thought to subsequently induce the
internalization of AQP2 as a means of reducing antidiuresis
and preventing renal stone formation (142, 154). Although the
underlying molecular mechanism for the effect on AQP2 is still
poorly understood, Sands et al. (142) identified in an elegant
study a signaling pathway linking renal water and calcium
metabolism, as in purified apical endosomes from inner med-
ullary collecting duct (IMCD) cells; they found besides AQP2
and the CaSR, PKC, PKC, and Gq/G11 GTP binding
proteins, the latter two of which had been reported earlier to
interact with the CaSR. In line with these findings, Procino et
al. (125) found later that CaSR-mediated downregulation and
internalization of AQP2 in transfected renal cells by extracel-
lular calcium coincide with a strong activation of PKCs,
reduced forskolin-induced cAMP levels, and increased F-actin
content. The role of decreased cAMP levels in hypercalcemia-
induced NDI is further corroborated by the finding of Wang et al.
(165) that treatment of such rats with cAMP-phosphodiesterase
inhibitors prevents polyuria and reduced AQP2 expression.
Urinary Tract Obstruction
Urinary tract obstruction is a serious clinical condition,
which in children is usually due to congenital abnormalities of
Fig. 1. Regulation of aquaporin-2 (AQP2)-
mediated water transport by vasopressin
(AVP). Shown is a nephron with a magnified
principal cell. In this cell, the vasopressin V2
receptor (V2R), stimulatory GTP binding
protein (Gs), adenylate cyclise (AC), ATP,
cAMP, and phosphorylated proteins (O-P)
are indicated. For details, see the text.
Invited Review
F258 CELL BIOLOGICAL ASPECTS OF V2R AND AQP2 IN NDI
AJP-Renal Physiol • VOL 291 • AUGUST 2006 • www.ajprenal.org
 o
n
 July 11, 2012
ajprenal.physiology.org
D
ow
nloaded from
 
the kidneys and urinary tract, whereas in adults is mostly
caused by stones, enlargement of the prostate, and urinary tract
neoplasms. After removal of the obstruction, a marked polyuria
develops, which is restored to normal in time, although a
somewhat decreased maximum concentrating ability persist for
a long time (43). Although the mechanism remains poorly
understood, several studies in rats, especially by the Frøkiær
team (41, 81, 82, 122), have shown that obstruction-induced
NDI is likely due to reduced expression of major renal sodium-
transporting proteins [NHE3, Na-K-ATPase, NaPi-2, NKCC1,
and the sodium-chloride cotransporter (NCC)] and AQP1–4,
all along the nephron (for a recent review, see Ref. 42). A
recent study shed some light on the underlying mechanism, as
Norregaard et al. (113) found that the reduction in AQP2,
NHE3, and NKCC1 expression in the inner medulla, but not in
other parts of the kidney, coincided with increased cyclooxy-
genase-2 (COX-2) expression and prostaglandin release from
interstitial cells in rats with bilateral ureteral obstructions.
Also, treatment with the COX-2 inhibitor parecoxib prevented
downregulation of these transporters. It remains to be deter-
mined whether COX-2 inhibitors can shorten the period of NDI
after the obstruction is removed.
Lithium-Induced NDI
Lithium, which is the drug of choice for treating bipolar
disorders, is successful in reducing both manic and depressive
symptoms in 70–80% of patients and reduces the excessive
mortality rate observed in this illness (27). Unfortunately,
development of NDI is a common side effect. Because 0.1% of
humans are on lithium therapy and severe forms of this side
effect present in 10–20% of patients, lithium-NDI is the
most common acquired form of NDI (150). Chronic lithium
treatment decreases the GFR (13) and, considering the narrow
therapeutic index of lithium (0.6–1.2 meq/l), toxicity resulting
from severe dehydration is a problem of significant clinical
importance in lithium-NDI. Moreover, lithium-NDI is associ-
ated with hyperchloremic metabolic acidosis, renal tubular
acidosis (35, 70, 107, 132), and increased natriuresis. Rat
studies revealed that lithium-NDI coincides with decreased
total AQP2 expression and a reduced expression of AQP2 in
the apical membrane (88). Further rat studies revealed that the
effect depends on the period of lithium treatment, as short-term
(10–14 days) treatment downregulates AQP2 expression with-
out affecting renal morphology, whereas long-term (i.e., 4 wk
or longer) treatment also causes an increase in intercalated cells
at the expense of principal cells (25, 70, 80). The lithium-
induced natriuresis is suggested to be due to the reduced
expression in some, but not all, renal segments, of several
salt-transporting proteins, such as NCC, the - and -subunits
of ENaC, and the Na-K-ATPase (80, 108, 109, 131). The
mechanism underlying the metabolic and distal tubular acido-
sis in lithium-NDI is poorly understood. Surprisingly, with
long term-lithium treatment, it coincides with strongly in-
creased expression levels of apical H-renal ATPase, which
cannot be explained by the increased number of intercalating
cells, and altered expression of several other acid-base trans-
porters (70).
Recent studies shed some light on the mechanisms underly-
ing the reduced AQP2 levels in lithium-NDI. As indicated for
electrolyte and obstructive NDI, the reduced AQP2 expression
in lithium-NDI might be due to a reduced interstitial osmolality
(131). Also, Rao et al. (126) arrived at the suggestion that
increased PGE2 expression, which counteracts AVP-induced
AQP2 total and plasma membrane expression, might explain
AQP2 reduction in lithium-NDI (126). In an elegant study,
these authors found that polyuria in COX-1-deficient mice
treated with lithium for 4 days resulted in increased COX-2
expression and PGE2 release from interstitial cells and that
polyuria and PGE2 release were blunted on inhibition of
COX-2 expression. Similar data were observed in Brattleboro
rats, indicating that the observed effects were independent
from AVP. In contrast, however, lithium-NDI due to a 4-wk
lithium treatment in rats coincided with reduced COX-1 and
COX-2 levels in the inner medulla, which were strongly
increased with dehydration (75). At present, an explanation for
these differences is lacking.
Analysis of direct effects of lithium on AQP2 expression
have been hampered by the availability of a cell line endog-
enously expressing AQP2 in response to AVP. Recently, such
a cell line was generated (49). We found that these murine
cortical collecting duct (mpkCCD) cells are well suited for
studying the effects of lithium on AQP2 in more detail, as
treatment with clinically relevant concentrations of lithium
resulted in a marked reduction in, and reduced plasma mem-
brane expression of, AQP2 (83). Surprisingly, lithium did not
affect AVP-induced cAMP generation, phosphorylation or sta-
bility of AQP2, or the phosphorylation of the AQP2 transcrip-
tion factor, the cAMP responsive element binding protein
(CREB). Instead, it caused a decrease in AQP2 mRNA levels,
indicated that lithium reduces AQP2 gene transcription or
mRNA stability. Although further data need to be obtained, an
effect of lithium on AQP2 gene transcription is in line with our
findings that lithium does not affect AQP2 protein levels in
transfected Madin-Darby canine kidney (MDCK) cells in
which AQP2 expression is directed from a non-AQP2-related
promoter (Shaw S, Li Y, et al., unpublished observations). Our
data seem to contradict earlier studies in which it was found
that lithium treatment of rats interfered with adenylate cyclase
activity, cAMP generation, and PKA activation in isolated
renal tubules (26). However, whereas these rats were chroni-
cally treated with lithium and, therefore, the observed effects
might be due to the changed cellular constitution of their renal
collecting ducts (25) and/or reduced sensitivity of the renal
collecting duct due to increased circulating AVP levels in
lithium-NDI rats (83), our data are obtained with only a 2-day
(cells) or short-term (rats) lithium treatment, periods at which
a changed cellular constitution of cell layer and renal tubules
was not observed (25).
CONGENITAL NDI
Congenital NDI can be divided into X-linked and autosomal
recessive and dominant NDI. Here, we will discuss the genes
and proteins involved in these forms of congenital NDI in
humans and those only found in animals.
X-Linked NDI
The X-linked and most prominent form of congenital NDI is
caused by loss-of-function mutations in the AVPR2 gene,
encoding the V2R (19, 85), which is a member of the family of
G protein-coupled receptors (GPCR; Fig. 2). Over 180 AVPR2
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gene mutations have been described (http://www.medicine.
mcgill.ca/nephros), of which many result in severe interference
with receptor signaling, thus making the principal cells of the
collecting duct insensitive to AVP. The molecular mechanism
underlying this insensitivity, however, differs among mutants.
As upcoming pharmacological treatments for NDI likely de-
pend on the underlying mechanism, we recently divided GPCR
mutations into general and particular V2R mutations in five
different classes according to their cellular fate (30, 129) (Fig.
3A and Table 1).
Class I comprises all mutations that lead to improperly
processed or unstable mRNA, like promoter alterations, exon
skipping, or aberrant splicing. This class also holds frame-shift
and non-sense mutations, which result in truncated proteins
like V2R-Q119X, -W293X, and -R337X.
Class II mutations are missense or insertion/deletion of one
or more nucleotide triplets, resulting in fully translated pro-
teins. Due to the mutation, however, mutant receptors are
misfolded and retained in the endoplasmic reticulum (ER), as
the ER is the organelle that has the cellular quality control over
proper folding and maturation of synthesized proteins. Mis-
folded proteins are subsequently mostly targeted for proteaso-
mal degradation (40). Intracellular entrapment of missense
V2R mutants and their rapid degradation likely represent the
most important cause for NDI, as 50% of the mutations in
V2R are missense mutations and cellular expression revealed
that most of these result in ER-retained proteins. The extent of
ER retention, however, may differ among mutants and may
represent differences in their folding state. Hermosilla et al.
(51) recently reported that of eight V2R mutants that are
Fig. 2. Proposed topology of the human V2R.
The V2R has 7 transmembrane domains with its
NH2 terminus extracellular and its COOH termi-
nus intracellular. The transmembrane domains are
connected by 3 extracellular (ECL1–3) and intra-
cellular (ICL1–3) loops. The N-glycosylation site
(at N22) in its NH2 terminus and the palmitoyl-
ated cysteines (C141–142) in its COOH terminus
are indicted. Bright amino acids are conserved
among V1R, V2R, and V3R.
Fig. 3. Cellular fate of V2R mutants in nephrogenic
diabetes insipidus (NDI) and their rescue. A: V2R
mutation classes in NDI. Shown is a schematic view
of a collecting duct cell. The different mutation
classes are indicated by roman numerals. Mutation
can lead to mRNA instability, splicing errors, and
nonsense mutations (I); endoplasmic reticulum (ER)
retention (II); impaired Gs coupling (III); impaired
AVP binding (IV); and mislocation in the cell (V).
See the text for details. B: pharmacological chaper-
ones rescue class II V2R mutants. Class II V2R
mutants are retained in the ER, but on binding of
cell-permeable antagonists (CPA), stabilization of
their structure allows them to exit the ER, mature in
the Golgi, and subsequently translocate to the
plasma membrane (1). At the membrane, displace-
ment of the CPA by AVP will allow restoration of
the cAMP cascade (2).
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retained, only three were strictly kept in the ER, whereas the
five other mutants were transported to the ER-Golgi interme-
diate compartment, followed by retrograde transport to the ER.
Class III comprises similar mutations to class II, but the
resulting mutants are not considered misfolded by the ER and
can continue their itinerary to the plasma membrane. However,
these mutations disturb binding of the stimulatory Gs protein,
leading to reduced activation of adenylate cyclase and thus
formation of cAMP.
Class IV mutations also result in full-length receptors ex-
pressed at the cell surface, but here the mutation interferes
with, or reduces, AVP binding. These mutations especially
involve residues thought to be in or close to the AVP binding
pocket, of which V2R-R202 is a clear example (2).
Finally, class V mutations allow normal protein synthesis
and maturation, but they cause misrouting to different or-
ganelles in the cell. The NDI R137H mutation, located in the
well-conserved DRY/H motif of GPCRs, is a member of this
class, as V2R-R137H is constitutively internalized from the
plasma membrane and therefore only briefly available to bind
AVP (10, 15).
Sometimes, mutants do not exert a full phenotype of a
particular class and then often also show features of another
class. For example, some V2R missense mutants are partially
ER retained (class II) but are also partially expressed in the
plasma membrane, where they might show a reduced G protein
coupling (class III) or AVP binding (class IV). Indeed, V2R-
R113W, -G201D, and -T204N stably expressed in polarized
MDCK cells are partially ER retained, whereas a considerable
fraction is expressed in the basolateral membrane (129). As
such, this provides an explanation for the observed small
antidiuretic response to high doses of DDAVP in NDI patients
harboring such mutations (124) (Table 1). For a full interpre-
tation of these increased urine osmolalities with DDAVP,
blood osmolalities and sodium levels are also important but
have only been reported for a few patients (Table 1).
Autosomal Recessive NDI
Approximately 10% of the patients diagnosed for NDI have
mutations in the AQP2 gene, which is mapped to chromosome
12q13 (34, 140). Of these, 90% suffer from recessive NDI.
Most, but not all (28, 34), of these patients are of consanguin-
eous lineage and have inherited two identical mutant AQP2
alleles. In total, 34 AQP2 mutations have been described, of
which 27 are involved in recessive NDI (Table 2). Of this
group, 78% comprise missense mutations. On expression of the
encoded mutants in cell systems, nearly all mutants were
misfolded and trapped in the ER (class II), followed by rapid
proteasomal degradation (31, 33, 84, 90, 92, 104, 152). Con-
Table 1. V2R mutations involved in NDI
Nucleotide Amino Acid Referred/Analysis Functionality
Conserved
(Location) Class Diagnosis Treatment
492TC L44P (5;72;99;116;117;129) F Y (tmd1) II 1 wk dD:NR
488TA I46K (120) F N (tmd1) II 5 yr ndD:NR
548TC L62P (5;72) ? Y (tmd1) II? 21, 53 mo dD:NR
545-553del 62-64 (18;129) G N (tmd1) II ? ?
574GA W71X (17) N (ICL 1) I ? dD:NR
612CA A84D (3) A N (tmd2) II ? ?
614GA D85N (61;120;130) F Y (tmd2) III 32 mo nD, dD-deh.:400
623GA V88M (72;160;163) ? Y (tmd2) II 16 mo ndD:NR; deh.:500, PS 158
692TC W99R (3) A Y (ECL1) II,
IV
? ?
671CT R104C (55;96) F Y (ECL1) II 8 days ndD:NR:dD:300;thiaz., DDAVP
674TG F105V (120) A Y (ECL1) IV ? ?
698CT R113W (72;136) F Y (tmd3) II,
IV
? dD-deh.:NR
749AT I130F (120;129) F N (tmd3) II 1 mo ndD:NR
771GA R137H (9;17;92;61;133;134;138;139;144) G Y (ICL2) II,
III,
V
? dD-deh.:NR (292):dD:400 PO(282)
860TA S167T (115;117;129;172) F N (tmd4) II 1 mo dD:NR
861CT S167L (72;115;117;129;170;172) A N (tmd4) II 2 wk, 8 mo ndD, dD:NR
902CT R181C (18;72;129;144;146) A N (tmd4) IV 6 mo ndD:NR
914GT G185C (145;158;160) A N (ECL3) IV 7,9,108,128,204 mo dD-deh.:300
963GA G201D (129;136) F Y (ECL3) II,
IV
? dD-deh.:400
965CT R202C (3;6;145;155;169) A N (ECL3) IV 18 mo ?
966-967 del R202 (2) A N (ECL3) IV ? dD:NR
972CA T204N (72;124;129;161) A N (ECL3) II 15 mo dD:NR; dD:200
975AG Y205C (51;124;158;160;163) A Y (ECL3) II 2 wk, 2.5 mo dD:NR
978TA V206D (72;124;128) A N (tmd5) II ? dD:NR
1431CT P322S (2;163) F Y (tmd7) III,
IV
10 mo, 8 yr dD-deh.:400
1476CT R337X (18;24;51;72;100;114;137;153;189) A N (C-tail) I 4 mo dD:NR, deh300, PS 189
V2R, vasopression V2 receptor; NDI, nephrogenic diabetes insipidus; F, functional; A, disturbed AVP binding; G, disturbed Gs protein binding; conserved
(Y) or not (N) between vasopressin receptors; tmd, transmembrane domain; ECL, extracellular loop; ICL, intracellular loop; dD, infusion with DDAVP; ndD,
nasal DDAVP; deh, dehydration; NR, nonresponsive; 400, urine 400 mosmol/kgH2O; PO, plasma osmolality in mosmol/kgH2O; PS, plasma sodium
(mosmol/kgH2O).
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sistent with their extensive degradation, AQP2 proteins could
not be detected in the urine of patients with recessive NDI due
to AQP2 gene mutations, in contrast to those of healthy
controls or of a female V2R NDI patient (32, 65). Although ER
retained, overexpression in oocytes, where a fraction of the
AQP2 mutants are found in the plasma membrane, revealed
that AQP2-L22V, -A47V, -G64R, -T125M, -T126M, -A147T,
and -V168M are functional as water channels on a molecular
level (23, 90, 92, 104). Interestingly, AQP2-V168M yielded a
less severe misfolding than other AQP2 mutants in NDI, which
might explain the relatively mild form on NDI in a Mexican
family encoding this mutant (20). In general, however, the
urine concentrating ability of patients with recessive NDI due
to AQP2 mutations are severely affected (urine osmolality
	100 mosmol/kgH2O), indicating that in vivo plasma mem-
brane expression of functional AQP2 mutants is negligible.
The inability of these AQP2 mutants to form heterotetramers
with wild-type AQP2 (wt-AQP2), leaving only the formation
of wt-AQP2 homotetramers, likely explains the healthy phe-
notype of the parents (64). For this, an increased wt-AQP2
expression from the normal allele does not seem to be neces-
sary, because the AQP2 heterozygote knockout mouse, which
has a healthy phenotype, expresses about half of AQP2 found
in normal mice (173).
Most mutations in autosomal recessive NDI are found in
between the first and the last transmembrane domain (Table 2).
As this segment forms the AQP2 water pore (105), the mis-
folding resulting from mutations in this part of the protein
illustrates the sensitivity of the pore to structural changes.
Recently, one mutation in recessive NDI was found outside
this region. Surprisingly, this mutation encodes the P262L
exchange in the AQP2 COOH tail, a location that was until
then destined to result in dominant instead of recessive NDI
(28). This mutation was found in two independent patients,
encoding, besides AQP2-P262L, AQP2-A190T and AQP-
R187C mutants. Expression in oocytes revealed that the latter
two mutants were ER retained (class II). The retention of
AQP2-P262L in intracellular vesicles of polarized MDCK cells
on stimulation with forskolin provided an explanation for its
involvement in NDI, as in the patient neither AQP2-P262L nor
AQP2-A190T/R187C would be expressed in the apical mem-
brane of principal cells. However, the observed retention in a
non-ER compartment was in still in line with a pattern encoun-
tered for AQP2 mutants in dominant NDI. Indeed, as found for
mutants in dominant NDI, AQP2-P262L escaped the ER and
formed heterotetramers with wt-AQP2, but not AQP2-A190T
or AQP-R187C. On coexpression with wt-AQP2, however,
wt-AQP2 appeared to target the wt-AQP2/AQP2-P262L com-
Table 2. AQP2 mutations involved in NDI
Nucleotide Amino Acid
Homozygous/
Heterozygous
Recessive/
Dominant Referred/Analysis Functionality
Conserved
(Location) Class Diagnosis Treatment
64CG L22V he3 r (23)/(152) P, (60%) N (tmd 1) II (64) dD
83TC L28P ho r (90)/(90) N (tmd 1) II 1 mo dD:NR
140CT A47V ho r (90)/(90) P (40%) N (tmd 2) II ? dD-deh.:NR
170AC Q57P he5 r (84)/(84) NF N (tmd 2) II ? dD:NR
190GA G64R ho r (162)/(31;92;162) P (20%) Y (b-loop) II 1 mo dD:NR
293AG N68S ho r (104)/(92) NF Y (b-loop) II 1.6 mo e:dD-deh.:300; dD:NR
211GA V71M ho r (90)/(90) NF Y (b-loop) II ? ndD:NR
253CT R85* ho r (163)/(163) I 2 mo dD:NR
299CT G100* ho r (53)/(53) I ? dD:NR
299GT G100V he5 r (84)/(84) NF N (tmd 3) II ? dD:NR
369delC Frameshift ho r (162)/(162) I ? ?
374CT T125M ho, he8 r (46;77)/(46;80) P, (25%) N (c-loop) II ? ?
377CT T126M ho r (92)/(46;82;104) P (20%) N (c-loop) II 6 mo dD-deh.:NR
439GA A147T ho r (104)/(92;104) F Y (d-loop) II 3 mo dD-deh.:NR
450TA D150E he7 r (47)/(47) NF Y (d-loop) II ? ?
502GA V168M he4, ho r (20;163)/(20) P (60%) N (tmd 8) II ? he:ndD:NR; ho:dD	200
523GA G175R ho, he8 r (46;77)/(46;90) NF Y (tmd 5) II ? ?
543CG C181W he3 r (23)/(102;152) NF N (e-loop) II (64) ?
553CG P185A ho r (90)/(90) NF Y (e-loop) II 1 wk ndD:NR
669CT R187C ho,he1 r (33;162)/(92;162) NF Y (e-loop) II 2 wk, 5 mo dD-den.:NR
928GA A190T he2 r (28;77)/(28;77) NF N (e-loop) II ? dD:NR
587GA G196D he7 r (47)/(47) NF N (e-loop) II ? NR
606GT W202C/
splice
ho r (116)/(116) Y (e-loop) I 4–8 wk dD:NR
c6061GA splice he6;all.2 r (90)/(90) (intr. 3) I 2 wk dD:NR
646TC S216P he1, he4 r (33)/(31;82) NF N (tmd 6) II 3 mo dD:NR
652delC Frameshift he6;all.1 r (90)/(90) N (tmd 6) I 2 wk dD:NR
721delG Frameshift he d (78)/(78) F N (C-tail) IV 12 mo ndD:NR; deh.:300
727delG Frameshift he d (91)/(91) F N (C-tail) IV ? dD:NR
761GT R254L he d (29)/(29) F N (C-tail) IV 	12 mo ?
763-772del Frameshift he d (78)/(78) F N (C-tail) IV 36 mo ndD:NR
772GA E258K he d (103)/(103) F N (C-tail) IV ? dD:300
779-
780InsA
Frameshift he d (62)/(62) F N (C-tail) IV 6–1 mo dD:NR:300
785CT P262L he2 r (28;77)/(28;77) F N (C-tail) IV ? dD:NR
812-818del Frameshift he d (78)/(78) F N (C-tail) IV 16 mo dD:incr.:deh.:300
AQP2, aquaporin-2; he, Heterozygous; ho, homozygous; all, allele; r, recessive; d, dominant; NF, nonfunctional; P, partial functional (level in % between
brackets); conserved (Y) or not (N) between AQP proteins; 300, urine 300 mosmol/kgH2O.
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plexes to the apical membrane, indicating that, in contrast to
AQP2 mutants in dominant NDI, the apical sorting signals of
wt-AQP2 overrule the retention signals in AQP2-P262L,
thereby explaining the involvement of AQP2-P262L in reces-
sive instead of dominant NDI. The cellular phenotypes of
patients in autosomal recessive and dominant NDI and their
parents are summarized in Fig. 5.
Autosomal Dominant NDI
Being diagnosed in only seven families, autosomal dominant
inheritance is the least prominent form of NDI. The mutations
identified in these families comprise nucleotide deletion, inser-
tion, as well as missense mutations (Table 2). By definition,
these mutations are only found in one AQP2 allele. As water-
selective AQPs are structurally similar and it was shown that,
while expressed as homotetramers, an AQP1 monomer is the
functional unit (59, 149, 159), we reasoned that AQP2 mutants
in dominant NDI should be able to interfere with the function-
ing of wt-AQP2. Indeed, on expression in oocytes, these AQP2
mutants were not ER retained and were able to form heterotet-
ramers with wt-AQP2 (64). Due to the mutation, however,
these molecularly functional AQP2 mutants were missorted
(class V) and, because of the formation of heterotetrameric
complexes with wt-AQP2, also targeted wt-AQP2 to other
subcellular destinations. Extrapolated to the principal cells of
patients, this would lead to severely decreased amounts of
AQP2 in the apical membrane, explaining the dominant mode
of inheritance of NDI in their families (64).
Clinical analyses of patients with recessive and dominant
NDI due to AQP2 mutations revealed three interesting differ-
ences (62, 78, 91, 103) (Table 2). First, the symptoms of NDI
(polydipsia, polyuria) are already noticeable at birth in reces-
sive NDI, whereas in dominant NDI they often become appar-
ent in the second half of the first year or later. Second, urine
osmolalities of patients with recessive NDI never exceed 200
mosmol/kgH2O, whereas those of dominant NDI are some-
times higher. Third, patients with dominant NDI sometimes
show a transient increase in urine concentration shortly after
DDAVP administration or dehydration. This transient increase
seems not to be related to the identified AQP2 mutation,
because some patients in the AQP2-insA family did not re-
spond. The observation that a dominant disease is subclinically
“milder” than the recessive form is not restricted to NDI,
because it is also found for long-QT syndrome, myotonia
congenita, osteochondrodysplasias, and Robinow syndrome/
brachydactyly (1, 164, 168, 175).
Interestingly, all AQP2 mutations in dominant NDI are
located in its COOH terminus (Figs. 4 and 5 and Table 2),
which underscores the importance of this segment in traffick-
ing of AQP2. Of the seven mutations described, six have
shown or are likely to introduce a missorting signal. The first
reported AQP2 mutant, AQP2-E258K, is missorted to the
Golgi complex in oocytes, but to late endosomes/lysosomes in
polarized cells (52, 103). This mutant is strongly retained in
oocytes. Deletion of a small segment containing the E258K
mutations greatly restored cell surface expression and water
permeability, indicating that the introduced Lys instead of the
loss of E258 caused the dominant feature (103). Although
starting at different positions, all 1 frameshift mutations
721delG, 727delG, del763–772, and del812–818 resulted in a
similarly extended COOH-terminal tail. In MDCK cells,
AQP2–727delG localized to late endosomes/lysosomes, and to
some extent the basolateral plasma membrane, whereas the
other three mutants were present exclusively in the basolateral
membrane (7, 78, 91). The molecular signature causing the
missorting of these AQP2 mutants has remained elusive. In
contrast, an adenosine insertion at position 779 (insA) found in
another patient yields a 2 reading frame shift, resulting in a
different and slightly extended COOH-terminal tail. Detailed
analysis in MDCK cells revealed that this mutant was trans-
ported to the basolateral membrane, due to the introduction of
two basolateral sorting signals in the changed COOH-terminal
segment (62).
Finally, one family with dominant NDI was found in which
R254 was exchanged for a leucine (29). In contrast to the
others, this mutation did not introduce a missorting signal, but
Fig. 4. Proposed topology of human AQP2. An AQP2
monomer consists of 6 transmembrane domains con-
nected by 5 loops (A–E) and its NH2 and COOH
termini located intracellularly. Loops B and E meet
each other with their characteristic NPA boxes in the
membrane to form the water-selective pore. N-glyco-
sylation (at N123) is indicated. Bright amino acids are
conserved among different AQPs.
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interfered with S256 phosphorylation of AQP2 by PKA. Con-
sequently, the formed wt-mutant complexes were retained in
intracellular vesicles that are likely similar to the storage
vesicles in which unstimulated wt-AQP2 accumulates. This
was supported by the similar subcellular distribution of AQP2-
R254L, unstimulated wt-AQP2, and AQP2-S256A, which
mimics nonphosphorylated AQP2, and their partial colocaliza-
tion with the early endosome antigen-1 (EEA-1) marker pro-
tein.
Genes in Nonhuman NDI
To identify the physiological role or proteins, gene deletion
by homologous recombination is often employed in mice.
Using this knockout strategy, mice lacking AQP2 or the V2R
appeared to suffer from severe NDI, resulting in perinatal death
(173, 174). In contrast, mice lacking AQP3, SPA-1, Foxa1,
CLC-K1, or all three nitric oxide synthase (NOS) isoforms, or
expressing overactive PDE-III, showed milder forms of NDI
(12, 76, 86, 93, 101, 106, 111, 156). While a role of AQP3 (exit
of water from principal cells) ands PDE-III (reduced intracel-
lular cAMP levels) in AVP-induced AQP2-mediated water
transport is obvious, this is not so clear for the others. The
signal-induced proliferation-associated gene-1 (SPA-1) pro-
tein, which is a GTPase-activating protein (GAP) for Rap1
containing a PDZ binding domain, directly bind AQP2 and has
a role in its routing. However, its precise function in AQP2
trafficking now needs to be uncovered. Foxa1 is a member of
the winged helix family of transcription factors and is ex-
pressed in the collecting ducts of the kidney. However, as the
expression of the V2R and AQP2 are not affected, its molec-
ular role is still unclear. As an increased interstitial tonicity is
essential for water reabsorption, it would be interesting to
determine whether the lack of Foxa1 reduces expression of
renal salt transporters. The kidney-specific CLC-K1 chloride
channel mediates transepithelial chloride transport in the thin
ascending limb of Henle’s loop (tAL) in the inner medulla and
is involved in the generation and maintenance of the hypertonic
medullary interstitium. While administration of DDAVP to
these mice did not increase urine concentration, it is at present
unclear whether this is only due to a reduced interstitial tonicity
or also to reduced principal cell V2R or AQP2 expression. NDI
in the triply nitric oxide synthase (NOS) knockout mice coin-
cided with reduced membranous AQP2 expression associated
with tubuloglomerular lesion formation and provide clear ev-
idence of a critical role of the NOS system in maintaining renal
homeostasis.
Although an occurrence of the loss of the three NOS proteins
in humans is unlikely to be encountered, there is no report
indicating that the lack of any of the above-mentioned genes
causes NDI in humans. In fact, in nearly all our congenital NDI
patients we have identified V2R or AQP2 gene mutations.
Moreover, the discovery that humans lacking AQP3 are with-
out any clinical phenotype (135) and that the lack of V2R or
AQP2 is lethal in mice but not in humans seem to indicate that
the urine concentrating mechanism is more sensitive in mice.
Therefore, whereas the above-mentioned proteins might have a
role in human renal osmoregulation, mutations in their genes
are likely to lead to a subclinical phenotype in human water
homeostasis or no phenotype at all.
THERAPIES IN CONGENITAL NDI
Conventional Therapies
The most important component of treatment for NDI is
replacement of urinary water losses by adequate supply of
fluid, in combination with a decreased solute diet to decrease
obligatory water excretion. Diuretics such as hydrochlorothia-
zide and amiloride have been shown to effectively lower urine
Fig. 5. Cellular fate of AQP2 mutants in the
different forms of autosomal recessive or
dominant NDI. Shown is a schematic repre-
sentation of a principal cell of the collecting
duct of patients suffering from autosomal
recessive NDI (28, 33) and their unaffected
parents. For patients in autosomal dominant
NDI, the carrier parent has a patient pheno-
type and is therefore not shown in this
scheme. For details on the specific AQP2
mutants, see the text.
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volume in NDI, which is, at least for hydrochlorothiazide,
more pronounced in combination with a low-salt diet (36, 71).
The combined administration of hydrochlorothiazide with ei-
ther a prostaglandin synthesis [or cyclooxygenase (COX)]
inhibitor such as indomethacin (2 mg kg
1 day
1) or the
potassium-sparing diuretic amiloride was shown to be much
more effective in reducing urine volume than the thiazide-
diuretic alone (4, 58, 73, 74, 97, 127). Long-term use of
prostaglandin-synthesis inhibitors, however, is often compli-
cated by gastrointestinal and hematopoietic side effects. In
addition, renal dysfunction has been described during indo-
methacin therapy, most often consisting of a reduction in GFR.
Because of the known gastrointestinal safety of selective
COX-2 inhibitors compared with nonselective COX inhibitors,
a potential role for these drugs in the treatment of NDI has been
put forward. In one male NDI infant, the effectiveness of a
specific COX-2 inhibitor (rofecoxib) in decreasing urinary free
water losses was indeed demonstrated (121). Nevertheless, in
view of the recent discovery that prolonged use of that partic-
ular COX-2 inhibitor can cause severe cardiac side effects
(148), we believe that COX-2 inhibitors should not be used in
the treatment of NDI until it has been strictly determined which
of these specific inhibitors are completely safe. However, while
decreasing urine volume to a great extent, these treatments do
not completely overcome the excess of water excretion, as
adult patients with this conventional treatment still void 8–10
liters/day. Therefore, efforts into development of tailored ther-
apies have been initiated.
Tailored Therapies
In general, renal gene therapy has been hampered by a low
level of accessibility and the absence of selectivity of gene
transfer techniques to and expression in particular renal cells
(54, 79). In contrast, however, with the realization that success
of pharmacotherapy depends on the cellular process disturbed
by the disease-causing mutation, tailored pharmacotherapy has
become highly promising:
Antibiotics to Bypass Stop Codons
A future therapy for patients harboring premature stop codon
mutations (class I) is based on the ability of aminoglycoside
antibiotics to cause translational read-through. Indeed, a gen-
tamicin analog caused read-through of nonsense V2R mutants
in vitro and in vivo (143, 147). However, the efficiency by
which aminoglycosides confer read-through depends strongly
on the nucleotides flanking the premature stop codon, and on
the compound used, and some aminoglycosides exert toxic
effects on the kidney, which severely limits their clinical use.
ANP and the cGMP Pathway
The paradigm for vasopressin signaling involves cAMP-
mediated PKA activation, which results in the functionally
critical phosphorylation of AQP2 on S256 in vitro and in vivo
(29, 45, 63, 68, 157). As the AQP2 S256 phosphorylation site
also fulfils the requirements for phosphorylation by cGMP
kinase, Brown and co-workers (21, 22) came to the brilliant
idea that the lack of cAMP generation in patients with X-linked
NDI might be bypassed by pathways that activate cGMP
kinase. Indeed, in an elegant study, they could show that acute
elevation of cGMP levels by nitric oxide (NO), which thus
plays an important role in renal water homeostasis (101),
L-arginine, and atrial natriuretic peptide (ANP), led to AQP2
membrane insertion in both transfected cells and regions of the
kidney collecting duct (21). This occurred without increasing
intracellular cAMP levels and is thus independent of the V2R
signaling pathway. Consistently, inhibitors of type 5 cGMP
phosphodiesterases, like sildenafil, also induced the phosphor-
ylation and plasma membrane translocation of AQP2 in these
specimen (22). In vivo, chronic ANP infusion also induced an
increased S256 phosphorylation and apical targeting of AQP2,
but as ANP also induces natriuresis, it is at present unclear
whether these effects are due to hypovolemia-induced in-
creases in AVP release (167). It will be exciting to uncover
whether ANP or other cGMP kinase-activating compounds
will be beneficial for patients with X-linked NDI.
“Pharmacological Chaperones” to Rescue V2R Mutants
Very promising are also the approaches recently developed
for class II V2R mutants. While their in vivo expression is
likely low, transient overexpression of class II mutant proteins
in oocytes or HEK293/COS cells, with which a small fraction
are often expressed in the plasma membrane, allows the deter-
mination of whether such mutants are molecularly functional.
Indeed, using such techniques, several (partially) ER-retained
V2R and AQP2 mutants in NDI appeared to be functional at
the molecular level, as the AQP2 mutants conferred water
permeability, whereas the V2R mutants were able to mediate a
cAMP response on stimulation with DDAVP (23, 90, 92, 104,
124, 129, 170). In line with these findings, some patients
harboring functional and partially ER-retained V2R mutants
showed an increased urine concentration in response to high
doses of AVP (95) (Table 1).
An important step forward in a putative treatment of these
patients was the discovery that stabilization of mutant receptors
by cell-permeable V2R antagonists, like SR121463B, aid in the
mutant’s folding, thereby facilitating their translocation to the
plasma membrane (99, 153) (Fig. 3B). Because of their assis-
tance in receptor folding, such cell-permeable ligands are
termed pharmacological chaperones (14, 98). Although V2Rs
with mutations at residues of major structural importance could
not be rescued (e.g., H80R, W164R, S167L), the plasma
membrane expression of most class II V2R mutants was
restored (172). To be of therapeutic use, the rescuing antago-
nist has to be displaced by AVP after translocation of the V2R
mutant to the basolateral membrane. As the competition be-
tween AVP and the rescuing ligand at the plasma membrane
will determine functional rescue, low-affinity V2R ligands, like
the V1R inverse agonist SR49059, are thought to be clinically
more successful than high-affinity compounds such as
SR121463B (15). Indeed, Bernier et al. (16) recently found that
SR49059 showed a small, but significant, reduction in water
intake and urine output in five NDI patients with missense V2R
mutations, thus demonstrating the proof-of-principle that phar-
macological chaperones can also rescue mutant V2R in vivo.
Of great importance for this treatment, the relatively high
blood levels of SR49059 came with a minimum of side effects,
which is due to their high specificity for the V2R. As several
other V1R and V2R antagonists have been developed and have
been or are close to FDA approval, it will be exciting to find
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out to what extent they are able to relieve X-linked NDI caused
by functional class II V2R mutants.
In conclusion, research on congenital NDI during the last 15
years has evolved from the identification of the genes involved
and analysis of the cellular fate of the V2R and AQP2 mutants
to the development of different strategies to bypass or over-
come the inability of V2R mutants in X-linked NDI to mediate
an antidiuretic response. While it is at present unclear whether
a remedy for autosomal NDI can be developed, further devel-
opment of the above-mentioned highly promising approaches
and, especially, clinical testing of these separate or combined
strategies in patients with X-linked NDI is anticipated to bring
us an exciting scientific and clinical future, as it will tell us
whether we can relieve or cure the major form of congenital
NDI, 50 years after its first discovery (87).
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